文献速递心外重症与机械循环支持

凝血酶原复合物浓缩物对心脏移植用血、费用及结局的影响

Impact of Prothrombin Complex Concentrate on Blood Use, Cost, and Outcomes in Heart Transplantation.
PubMed 文献 · Ann Thorac Surg · 2018-02-15

本研究回顾性比较了60例左心室辅助装置(LVAD)桥接心脏移植患者中,传统华法林逆转用新鲜冰冻血浆与4因子凝血酶原复合物浓缩物(PCC)对输血需求、血库费用及临床结局的影响。PCC组术中输血更少、延迟胸骨闭合更少,但血库总费用更高,两组血栓栓塞事件及院内死亡无差异。

要点

  • PCC组术中新鲜冰冻血浆、冷沉淀及总血制品用量均少于无PCC组。
  • PCC组延迟胸骨闭合发生率低于无PCC组(3% vs 23%,p=0.05)。
  • PCC组血库总费用高于无PCC组($4,949 vs $3,677,p=0.01)。

核心结论

  • 尽管费用更高,PCC减少了以LVAD桥接的心脏移植受者的输血需求及延迟胸骨闭合,作者认为这支持其替代传统华法林逆转。

研究设计与样本

  • 回顾性综述纳入60例连续接受心脏移植的LVAD受者,分为无PCC组30例(接受新鲜冰冻血浆)和PCC组30例(接受PCC)。
  • 比较患者特征、术中及术后输血需求、短期临床结局和血库费用,并用多元线性回归评估PCC与输血需求的关联。

主要发现

  • PCC组患者更年轻(50 ± 11 vs 57 ± 13岁,p = 0.02),缺血性心肌病比例更低(23% vs 60%,p = 0.01),既往胸骨切开超过一次的比例更高(7% vs 30%,p = 0.04),术前血红蛋白更高(11.8 ± 1.8 vs 10.4 ± 1.8 g/dL,p = 0.01)。
  • PCC组体外循环时间显著更短(185 vs 217分钟,p = 0.01),术中接受的新鲜冰冻血浆更少(2 vs 5单位,p = 0.03)、冷沉淀更少(0 vs 2单位,p = 0.05)、总血制品更少(9 vs 13.5单位,p = 0.03),需要延迟胸骨闭合的可能性更低(3% vs 23%,p = 0.05)。
  • 多元线性回归显示,PCC与术中输血减少显著相关(β = -6.09,p = 0.02)。
  • 两组血栓栓塞事件或院内死亡无差异。
  • PCC组血库总费用为$4,949,无PCC组为$3,677(p = 0.01)。

临床怎么用

  • 作者认为,尽管PCC费用更高,但其减少了以LVAD桥接的心脏移植受者的输血需求及延迟胸骨闭合,支持其替代传统华法林逆转。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular assist device (LVAD) recipients undergoing heart transplantation have increased bleeding risk. We compared conventional warfarin reversal with fresh frozen plasma vs 4-factor prothrombin complex concentrate (PCC) and the effect on transfusion requirements, blood bank costs, and clinical outcomes. METHODS: A retrospective review identified 60 consecutive LVAD recipients undergoing heart transplantation divided into two groups: 30 (no PCC) received fresh frozen plasma and 30 (PCC) received PCC. Patient characteristics, intraoperative and postoperative transfusion requirements, short-term clinical outcomes, and blood bank costs were compared. PCC association with transfusion requirements was assessed by multivariate linear regression. RESULTS: Patients who received PCC were younger (50 ± 11 vs 57 ± 13 years, p = 0.02), fewer had ischemic cardiomyopathy (23% vs 60%, p = 0.01), had more than one prior sternotomy (7% vs 30%, p = 0.04), and had higher preoperative hemoglobin (11.8 ± 1.8 vs 10.4 ± 1.8 g/dL, p = 0.01). The PCC group had a significantly shorter bypass time (185 vs 217 minutes, p = 0.01), received less fresh frozen plasma (2 vs 5 units, p = 0.03), cryoprecipitate (0 vs 2 units, p = 0.05), and total blood products (9 vs 13.5 units, p = 0.03) intraoperatively, and was less likely to require delayed sternal closure (3% vs 23%, p = 0.05). On multivariate linear regression, PCC was significantly associated with decreased intraoperative transfusion (β = -6.09, p = 0.02). There was no difference in thromboembolic events or in-hospital death. Total blood bank costs were $4,949 for PCC and $3,677 for no PCC (p = 0.01). CONCLUSIONS: Although more costly, PCC reduced transfusion requirements and delayed sternal closure in heart transplant recipients bridged with LVAD, justifying its use over traditional warfarin reversal.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wu DW, Xia Y, Uelinger J, et al. Impact of Prothrombin Complex Concentrate on Blood Use, Cost, and Outcomes in Heart Transplantation. Ann Thorac Surg. 2018. PMID: 29397934. doi:10.1016/j.athoracsur.2017.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。